Journalists working on stories related to high-risk pregnancies or the Society for Maternal-Fetal Medicine can contact Greg Phillips, Director of Communications, at press@smfm.org for referrals to MFM experts and to request additional information. The press office is open Monday through Friday from 9:00 AM to 5:00 PM ET.
The Society for Maternal-Fetal Medicine today issued its first evidence-based clinical guidance for diagnosing and treating cancer during pregnancy, Consult Series #76. Continue Reading
The Society for Maternal-Fetal Medicine is pleased to announce this year’s awards presented at the SMFM 2026 Pregnancy Meeting™ in Las Vegas, NV. Continue Reading
The increased number of state-level abortion restrictions in the U.S. was associated with a parallel increase in maternal deaths between 2005 and 2023, according to new research presented today at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting™. Continue Reading
First-time mothers who were randomized to receive a smartphone app called Baby2Home for the first year after giving birth reported significantly fewer symptoms of stress, depression, and anxiety, as well as better overall health, compared to first-time mothers who received usual postpartum care. Continue Reading
Coding Tip: Remote Physiological Monitoring (RPM) The Society for Maternal-Fetal Medicine (SMFM) Coding Committee; Trisha Malisch, CCS-P, CPC, COBGC Introduction Remote Physiological Monitoring (RPM) continues to expand as an important tool in patient care management, allowing... Continue Reading
The Society for Maternal-Fetal Medicine (SMFM) is pleased to announce that Jerasimos Ballas, MD, MPH; Catherine S. Eppes, MD, MPH; Moeun Son, MD, MSCI; and Sarahn M. Wheeler, MD, MHSc, have been elected to the SMFM Board. Continue Reading
Prepregnancy counseling, assembling multidisciplinary care teams, and referring to centers with expertise are critical in managing pregnant patients with heart failure to optimize maternal and newborn health outcomes, according to new guidance issued by SMFM. Continue Reading
By: Adam K. Lewkowitz, MD, MPHS, and Emily S. Miller, MD, MPH On July 21, 2025, the Food and Drug Administration (FDA) convened a roundtable panelist discussion on the use of selective serotonin reuptake inhibitors (SSRIs), a class of antidepressant medication, in pregnancy. The FDA... Continue Reading
As experts in high-risk pregnancies, the Society for Maternal-Fetal Medicine (SMFM) and its members are alarmed by the unsubstantiated and inaccurate claims made by FDA panelists concerning maternal depression and the use of SSRI antidepressants during pregnancy. Continue Reading
The Society for Maternal-Fetal Medicine (SMFM) is deeply disappointed in today’s final vote by the House of Representatives resulting in the passage of H.R. 1. The deep cuts to the Medicaid program contained in this legislation jeopardize the insurance coverage millions of... Continue Reading
SMFM recommends that each state in the US have an active maternal mortality review committee (MMRC) and calls for each to meet a list of nine minimum standards. Continue Reading
By Brenna L. Hughes, MD, MSc, and Naima T. Joseph, MD In late February 2025, the first confirmed measles-related death in the United States in a decade was reported when an unvaccinated school-aged child in West Texas died. A second measles-related death of a child in Texas is under... Continue Reading
